Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
- Japan’s Biosimilar Market to Rise to 31.4 Billion Yen in 2017: Fuji Keizai
May 19, 2015
- Sanofi Launches Menactra, Preventive Vaccine for Invasive Meningococcal Diseases
May 19, 2015
- Takeda Sees Lower Japan Sales for FY2015 on Generic Pressure
May 18, 2015
- Takeda Incurs Huge Red Ink on Actos Settlement, CEO Says Financial Uncertainty Lessened
May 18, 2015
- Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
- Takeda Discontinues Development of Bipolar Disorder Treatment TAK-375SL
May 18, 2015
- Masanobu Kambara Becomes UCB Japan President
May 18, 2015
- Mochida Terminates License Deal with US Merck for Type 2 Diabetes Treatment
May 18, 2015
- MTPC Files Remicade for Kawasaki Disease
May 18, 2015
- Daiichi Sankyo Profit Quintuples on Gains from Ranbaxy-Sun Merger
May 15, 2015
- Eisai Earnings Pummeled by Generic Erosions in Japan, US
May 15, 2015
- Mitsubishi Chemical Group to Strengthen Presence in Field of Regenerative Medicine by Acquiring Clio Inc.
May 15, 2015
- Vital KSK Holdings Names Taisuke Murai as President
May 15, 2015
- Kyorin Holdings Names Minoru Hogawa as Next President
May 15, 2015
- Wider Indications Will Give Edge to Plavix AGs: Nichi-Iko Pres.
May 14, 2015
- Takeda Halts PIII Study of Aurora A Kinase Inhibitor for Peripheral T-cell Lymphoma
May 14, 2015
- Blopress AG Gives Lift to ASKA Sales and Profits
May 13, 2015
- Ono’s Operating Profit Declines 40%; NHI Price Reductions, Generics Had Major Negative Impact
May 13, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…